Markets

Mangoceuticals’ MangoRx IP Secures $2.5M Investment From Strategic Investors, Receives Initial $1.75M Tranche

Oct 1, 2026 · 03:52 PM ET· updated 7h ago

Subsidiary-Level Investment Provides Capital to Advance Commercialization of the Company’s Antiviral Intellectual Property Portfolio with No Issuance of MGRX Common StockDALLAS, TEXAS, Oct. 01, 2026 (GLOBE NEWSWIRE) --

Why It Matters

Mangoceuticals raised $2.5 million to develop antiviral medicines. This shows investors believe in the science behind their drug ideas.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

MGRX0.42

-0.00 (-0.96%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.